MX2023011873A - Compuestos de oxazepina y sus usos en el tratamiento del cancer. - Google Patents

Compuestos de oxazepina y sus usos en el tratamiento del cancer.

Info

Publication number
MX2023011873A
MX2023011873A MX2023011873A MX2023011873A MX2023011873A MX 2023011873 A MX2023011873 A MX 2023011873A MX 2023011873 A MX2023011873 A MX 2023011873A MX 2023011873 A MX2023011873 A MX 2023011873A MX 2023011873 A MX2023011873 A MX 2023011873A
Authority
MX
Mexico
Prior art keywords
treatment
cancer
oxazepine compounds
compounds
oxazepine
Prior art date
Application number
MX2023011873A
Other languages
English (en)
Inventor
Steven Do
Michael Siu
Sushant Malhotra
Binqing Wei
Guosheng Wu
Yun- Xing CHENG
Aijun Lu
Limin Cheng
Jack Alexander Terrett
Elizabeth H Kelley
Cheng Shao
Jianfeng Xin
Lewis J Gazzard
Samantha Alyson Green
Matthew Leo Landry
Mingtao He
Benjamin David Ravetz
Yinlei Sun
Yulai Zhang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2023011873A publication Critical patent/MX2023011873A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente se proporcionan compuestos acíclicos de oxazepinilo útiles en el tratamiento de cánceres.
MX2023011873A 2021-04-08 2022-04-06 Compuestos de oxazepina y sus usos en el tratamiento del cancer. MX2023011873A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021085959 2021-04-08
PCT/US2022/023573 WO2022216762A1 (en) 2021-04-08 2022-04-06 Oxazepine compounds and uses thereof in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2023011873A true MX2023011873A (es) 2023-10-17

Family

ID=81387302

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011873A MX2023011873A (es) 2021-04-08 2022-04-06 Compuestos de oxazepina y sus usos en el tratamiento del cancer.

Country Status (11)

Country Link
EP (1) EP4320132A1 (es)
JP (1) JP2024513881A (es)
KR (1) KR20230167386A (es)
CN (1) CN117083279A (es)
AR (1) AR125304A1 (es)
AU (1) AU2022254674A1 (es)
BR (1) BR112023020773A2 (es)
CA (1) CA3215949A1 (es)
MX (1) MX2023011873A (es)
TW (1) TW202304934A (es)
WO (1) WO2022216762A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023172737A1 (en) * 2022-03-11 2023-09-14 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024032702A1 (en) * 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2024041573A1 (en) * 2022-08-25 2024-02-29 Zai Lab (Shanghai) Co., Ltd. Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
WO2024085661A1 (en) * 2022-10-18 2024-04-25 Ildong Pharmaceutical Co., Ltd. Novel triheterocyclic compounds
WO2024083168A1 (en) * 2022-10-19 2024-04-25 Genentech, Inc. Oxazepine compounds comprising a 6-aza moiety and uses thereof
WO2024112654A1 (en) 2022-11-21 2024-05-30 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JP2020519589A (ja) * 2017-05-11 2020-07-02 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物
TW202012415A (zh) * 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
SG11202109451TA (en) * 2019-03-05 2021-09-29 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
CN112574224A (zh) * 2019-09-30 2021-03-30 上海迪诺医药科技有限公司 Kras g12c抑制剂及其应用

Also Published As

Publication number Publication date
JP2024513881A (ja) 2024-03-27
BR112023020773A2 (pt) 2024-01-30
TW202304934A (zh) 2023-02-01
CA3215949A1 (en) 2022-10-13
CN117083279A (zh) 2023-11-17
WO2022216762A1 (en) 2022-10-13
KR20230167386A (ko) 2023-12-08
AR125304A1 (es) 2023-07-05
EP4320132A1 (en) 2024-02-14
AU2022254674A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
MX2023011873A (es) Compuestos de oxazepina y sus usos en el tratamiento del cancer.
MX2023009135A (es) Compuestos de oxazepina tetraciclica y usos de estos.
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12021550152A1 (en) Anti-cd112r compositions and methods
AR058505A1 (es) Combinaciones antineoplasicas de temsirolimus y malato de sunitinib
TW200612918A (en) Lonidamine analogs
GEP20237458B (en) Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MX2020012091A (es) Composiciones anti-cd24 y usos de las mismas.
ATE443724T1 (de) Antikrebs-antikörper mit reduzierter komplementfixierung
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
SG10201809411PA (en) Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
MX2022000726A (es) Anticuerpos inmunomoduladores y metodos de uso de los mismos.
MX2022012621A (es) Enlazadores de variantes de carga.
MX2019009354A (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer.
MX2019009356A (es) Sulfinilpiridinas y su uso en el tratamiento del cancer.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
FR3096259B1 (fr) conjugués anticorps-médicament et leur utilisation en thérapie
FR3107648B1 (fr) conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie
MX2021001765A (es) Tratamiento del linfoma follicular reicindido.
MX2023007113A (es) Peliculas solubles en agua, articulos de dosis unitaria solubles en agua y metodos de fabricacion y uso de los mismos.
CY1124183T1 (el) Συζευγματα αντισωματος εναντι-sez6 φαρμακου και μεθοδοi χρησης
JOP20210144A1 (ar) أجسام مضادة للبيريوستين واستخداماتها
MX2022016232A (es) Marcadores para uso en metodos para tratar canceres con conjugados de anticuerpo y farmaco (adc).